Introduction to XELSTRYM
XELSTRYM (dextroamphetamine) is a groundbreaking transdermal system, the first and only FDA-approved amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older. Approved by the FDA in March 2022, XELSTRYM is developed by Noven Pharmaceuticals, Inc., a subsidiary of Hisamitsu Pharmaceutical Co., Inc.[1][4].
Market Context for ADHD Treatments
The ADHD market is poised for significant growth, driven by several key factors. The global ADHD market is expected to grow at a CAGR of 6.9% during the forecast period of 2022-2027. This growth is fueled by the increasing prevalence of ADHD, rising healthcare spending, and the approval and commercialization of new treatments[3].
Unique Selling Points of XELSTRYM
XELSTRYM stands out in the ADHD treatment market due to its innovative delivery system. Here are some unique aspects:
- Transdermal Delivery: XELSTRYM is the first FDA-approved transdermal amphetamine patch, offering a once-daily application for 9 hours. This can enhance patient compliance and reduce the need for multiple daily doses[1][4].
- Convenience: The patch is easy to apply and remove, making it a convenient option for both adults and children.
- Controlled Release: The transdermal system provides a controlled release of dextroamphetamine, which can help in maintaining consistent drug levels throughout the day.
Market Demand and Growth Potential
The demand for ADHD treatments is on the rise, driven by an increasing number of diagnoses and a growing awareness of the condition. In the United States alone, an estimated 8,716,972 adults have ADHD, resulting in significant healthcare costs and a high societal burden[3].
The introduction of XELSTRYM is expected to capture a significant share of this growing market due to its unique delivery mechanism and the convenience it offers. As more healthcare providers and patients become aware of this new treatment option, the demand for XELSTRYM is likely to increase.
Pricing and Cost Considerations
XELSTRYM is currently available as a brand-name drug only, with no generic version available. The cost for XELSTRYM transdermal films varies based on the dosage but generally falls within a similar price range:
- Cost per Unit: For a 30-day supply, the cost is approximately $521.42, with each unit costing around $17.38, regardless of the dosage strength (4.5 mg/9 hours, 9 mg/9 hours, 13.5 mg/9 hours, or 18 mg/9 hours)[2].
Price Projections
Given the unique position of XELSTRYM in the market and the growing demand for ADHD treatments, here are some price projection considerations:
- Short-Term: In the immediate future, prices are likely to remain stable as the drug establishes its market presence. However, there could be minor fluctuations due to stock shortages or other market variables[2].
- Long-Term: As the market grows and more patients are prescribed XELSTRYM, the demand could lead to slight price increases. However, competition from other ADHD treatments and potential future generic versions could mitigate these increases.
- Insurance and Patient Assistance: The cost to patients may be reduced through insurance plans, copay cards, and patient assistance programs, which could impact the overall revenue but not the list price of the drug.
Competitive Landscape
The ADHD treatment market is highly competitive, with several established drugs and new approvals. For instance, recent approvals include Azstarys (KemPharma) and Qelbree (Supernus Pharmaceuticals), which also target the ADHD market[3].
XELSTRYM's unique transdermal delivery system sets it apart, but it will need to compete with oral and other forms of ADHD medications. The market share will depend on how effectively Noven Pharmaceuticals can market and distribute XELSTRYM, as well as the acceptance of the transdermal patch by healthcare providers and patients.
Side Effects and Safety Considerations
While XELSTRYM offers a convenient and effective treatment option, it comes with several serious side effects and warnings, including:
- Cardiovascular Risks: Serious heart problems, increased blood pressure, and heart rate.
- Psychiatric Problems: Mental health issues such as anxiety, depression, and psychosis.
- Peripheral Vasculopathy: Including Raynaud’s phenomenon.
- Growth Suppression: In children, regular monitoring of height and weight is necessary[1][4][5].
These safety considerations may impact the adoption rate and long-term market performance of XELSTRYM.
Conclusion
XELSTRYM is poised to make a significant impact in the ADHD treatment market due to its innovative transdermal delivery system. With the ADHD market expected to grow substantially, XELSTRYM is well-positioned to capture a significant share. However, its success will depend on various factors including pricing, competition, and patient acceptance.
Key Takeaways
- Innovative Delivery: XELSTRYM is the first FDA-approved transdermal amphetamine patch for ADHD.
- Market Growth: The ADHD market is expected to grow at a CAGR of 6.9% from 2022-2027.
- Pricing: Currently priced around $521.42 for a 30-day supply, with potential for minor fluctuations.
- Competition: Faces competition from other ADHD treatments but stands out due to its unique delivery system.
- Safety Considerations: Associated with serious side effects, necessitating careful monitoring.
FAQs
Q: What is XELSTRYM used for?
A: XELSTRYM is used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older.
Q: How is XELSTRYM administered?
A: XELSTRYM is administered via a transdermal patch that is applied to the skin once daily for 9 hours.
Q: What are the common side effects of XELSTRYM?
A: Common side effects include decreased appetite, headache, insomnia, tics, abdominal pain, vomiting, nausea, irritability, increased blood pressure, and increased heart rate.
Q: Is XELSTRYM available as a generic?
A: No, XELSTRYM is currently available only as a brand-name drug.
Q: How much does XELSTRYM cost?
A: The cost for a 30-day supply of XELSTRYM is approximately $521.42, depending on the pharmacy and dosage strength.
Sources
- PR Newswire: XELSTRYM™ (dextroamphetamine) transdermal system, CII, to be revealed as available soon at the 2023 American Professional Society of ADHD and Related Disorders (APSARD) Conference.
- Drugs.com: Xelstrym Prices, Coupons, Copay Cards & Patient Assistance.
- Mordor Intelligence: Attention Deficit Hyperactivity Disorder Market Size & Share Analysis.
- Drugs.com: Xelstrym (dextroamphetamine) FDA Approval History.
- Noven Pharmaceuticals: XELSTRYM.
